The Greatest Guide To pentobarbital sodium contraindications
The Greatest Guide To pentobarbital sodium contraindications
Blog Article
pentobarbital will reduce the extent or effect of buprenorphine buccal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
pentobarbital will lessen the extent or effect of atogepant by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Closely. Recommended atogepant dosage with concomitant usage of sturdy or average CYP3A4 inducers is thirty mg or sixty mg qDay.
pentobarbital will lower the extent or effect of bosentan by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Unknown.
pentobarbital will lower the level or effect of ramelteon by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
CONTRAINDICATIONS Barbiturates are contraindicated in patients with acknowledged barbiturate sensitivity. Barbiturates are contraindicated in individuals with a background of manifest or latent porphyria.
pentobarbital will lessen the level or effect of bedaquiline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Stay away from or Use Alternate Drug. Keep away from coadministration of bedaquiline with more info solid CYP3A4 inducers as a consequence of potential for lessened therapeutic effect
pentobarbital will lower the level or effect of methadone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
fentanyl transdermal and pentobarbital each maximize sedation. Prevent or Use Alternate Drug. Limit use to clients for whom alternative therapy solutions are inadequate
pentobarbital will minimize the extent or effect of nitrendipine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Not known.
pentobarbital will decrease the extent or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
pentobarbital will lessen the level or effect of lonafarnib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is a delicate CYP3A4 substrate. Coadministration with strong or reasonable CYP3A4 inducers is contraindicated.
pentobarbital will minimize the level or effect of rabeprazole by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unknown.
pentobarbital will reduce the level or effect of cobimetinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Stay away from coadministration. Solid or reasonable CYP3A inducers could lower cobimetinib systemic exposure by >80% and cut down its efficacy.
pentobarbital will minimize the extent or effect of imatinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unidentified.